Beautiful Countryside 2025 Annual Performance Release: Profit Soars by 41%

DoNews, March 27 - On March 27, Beautiful Pastoral Medical Health (02373.HK, hereinafter referred to as “Beautiful Pastoral” or “the Group”) officially released its annual performance report for 2025. Throughout the year, the Group’s revenue, profit, and cash flow experienced high-quality growth across the board, showcasing the strong growth resilience of an industry leader.

In 2025, Beautiful Pastoral Group’s profitability achieved a leap forward, with total revenue reaching 3 billion yuan, a year-on-year increase of 16.7%; gross margin improved to 49.1%, up 2.8 percentage points year-on-year; adjusted net profit surged to 380 million yuan, a significant year-on-year increase of 41.0%, with an adjusted net profit margin of 12.7%, up 2.2 percentage points, marking a new level of profitability.

Additionally, the Group continued to demonstrate its “cash cow attributes.” In 2025, the net cash flow generated from operating activities reached 1 billion yuan, a substantial year-on-year growth of 25.4%; as of December 31, 2025, the total amount of cash and cash equivalents held by the Group reached 2.59 billion yuan, a net increase of 41.6% year-on-year, providing ample momentum for the Group’s strategic investments and shareholder returns.

As a core foundational business, Beautiful Pastoral Group’s beauty and health services experienced robust growth against the trend. In 2025, this segment’s revenue reached 1.66 billion yuan, a year-on-year increase of 14.9%; gross margin improved by 1.2 percentage points to 41.9%; while achieving high-quality growth, the Group also anchored its long-term development strategy, officially launching its super supply chain strategy in 2025, with future product research and development expanding into three major models: globally selected products, international brand collaborations, and joint research with internationally renowned laboratories.

In February 2026, Beautiful Pastoral announced a strategic partnership with the globally renowned skincare brand Shiseido, deepening collaboration across multiple dimensions such as brand influence, service experience, and co-creation in scientific research.

Consumer medical services combine medical value attributes with consumer elasticity, representing a high-quality track carrying long-term structural opportunities. Over the past 16 years, Beautiful Pastoral has built its consumer medical capabilities from scratch, currently establishing 38 consumer medical institutions nationwide. In 2025, the overall revenue of the consumer medical segment reached 1.34 billion, a year-on-year increase of 18.9%, accounting for 44.8% of total revenue, becoming an important driver of growth.

Specifically, in 2025, Xiuker Medical Beauty services achieved revenue of 1.02 billion yuan, a year-on-year increase of 9.6%, with gross margin significantly increasing by 3.6 percentage points to 55.9%; additionally, Xiuker Medical Beauty precisely targeted the “anti-aging research” track, holding a brand upgrade launch event in March 2026, creating a comprehensive product blueprint for “early aging anti-aging, freeze-age anti-aging, reverse-age anti-aging,” officially starting a new era of Xiuker’s research on anti-aging.

At the same time, in the field of sub-health medical services, Yanyuan Medical also experienced explosive growth. In 2025, Yanyuan Medical’s revenue reached 330 million yuan, a year-on-year increase of 62.2%, with revenue share surpassing 10% for the first time; gross margin rose to 64.3%, up 6.1 percentage points year-on-year; the functional medicine segment’s revenue increased by 101% year-on-year, leveraging a self-developed AI model to achieve “personalized treatment plans for everyone” and 7x24 all-day service; the female special care segment’s revenue grew by 64%, continuing to expand its service landscape, constructing a “prevention-treatment-anti-aging” women’s health medical service.

In 2025, Naireer’s single-store revenue increased from 5.75 million yuan before the acquisition to 8.1 million yuan, with adjusted net profit margin significantly rising from 6.5% to 10.5%.